预约演示
更新于：2025-05-30
Bromfenac Sodium
溴芬酸钠
更新于：2025-05-30
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
72
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
418
项与 溴芬酸钠 相关的文献（医药）2025-05-01Retinal cases & brief reports
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Miyata, Mana ; Azuma, Keiko ; Obata, Ryo
Background/Purpose::
Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
Methods::
Case report.
Results::
(Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti–vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti–vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
2025-03-01VETERINARY OPHTHALMOLOGY
Low‐dose intravitreal injection of 4 mg preservative‐free gentamicin and superficial lamellar keratectomy combined with modified Gundersen grafts to control chronic heterochromic iridocyclitis and secondary keratitis in horses
Article
作者: Charnock, Lauren N. ; McMullen, Richard J.
Abstract:
Objective:
To describe a combined treatment approach for heterochromic iridocyclitis and secondary keratitis (HIK) in horses.
Animal Studied:
A total of 15 horses (16 eyes).
Procedures:
Sixteen eyes from 15 horses (mean age 14.1 years, range 6–26 years) received low‐dose (4 mg) intravitreal preservative‐free gentamicin injection (IVGI) and modified Gundersen grafts with standing sedation and local anesthesia following a clinical diagnosis of HIK. Additional therapies of suprachoroidal triamcinolone (8 mg) injection, episcleral bromfenac implants, and suprachoroidal cyclosporine implants were performed in individual cases. Leptospira titers were also reported when available.
Results:
The most frequent ophthalmic findings were pigmented keratic precipitates (n = 15/16 eyes, 94%), corneal edema (n = 14/16 eyes, 88%), and pigmented cells suspended in the anterior chamber (n = 7/16 eyes, 44%). Postoperative treatment generally consisted of topical and systemic NSAIDs, topical antibiotics, and a topical mydriatic agent. Complications included persistent corneal edema (7/16, 44%), corneal ulceration (6/16, 38%), graft failure requiring revision (2/16, 13%), stromal abscess (1/16, 6%), surgery site infection (1/16, 6%), and suspected retinal degeneration following IVGI (1/16, 6%). One case was enucleated 6 months after treatment (1/16, 6%). Of the 12 eyes with at least 3 months of post‐treatment follow‐up, 10 were comfortable and visual with static or improved symptoms of HIK.
Conclusions:
This multimodal treatment approach aims to address both the anterior uveitis and endothelial decompensation frequently seen in horses with HIK. The surgery can be performed under standing sedation. Continued evaluation and long‐term follow‐up is necessary in all horses with HIK.
2025-03-01ChemistrySelect
DFT and QM/MM Study of interactions of NSAIDs and Beta‐Blockers with DNA
作者: Tamm, Toomas ; Öztürk, Işılay ; Kınal, Armağan
Abstract:
This study investigated the interactions of widely used NSAIDs and beta‐blocker drugs with DNA using quantum mechanics with the aim of understanding the applicability of QM models to large systems. Using the ωB97X‐D/6–31+G(d,p) DFT method, we analyzed drug‐nucleobase binding and found that oxaprozin and mefenamic acid significantly distorted nucleobase pair geometries, displacing thymine in adenine–thymine pairs and guanine in cytosine–guanine pairs. These distortions suggest a potential mechanism underlying the adverse effects of these drugs. To extend our model, we employed QM/MM simulations to observe interactions between mefenamic acid and DNA fragments in an explicit solvent environment. Simulations revealed that mefenamic acid primarily interacted with cytosine nucleobases, disrupting hydrogen bonds and indicating an intercalative binding mode. Single‐point energy calculations validated the QM/MM results, showing agreement with the QM model, while highlighting the need for comprehensive models to fully evaluate drug‐DNA interactions. Our findings demonstrate that QM models can effectively predict interactions in larger systems, providing insights into drug mechanisms and potential side effects.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 蓋鬱鏇網範蓋選壓選鹽(餘觸襯艱夢齋壓鏇鬱願) = 夢齋廠範齋餘壓鬱窪鏇 遞衊鹽獵築選繭壓鹹廠 (餘築淵壓願遞鑰製觸願, 15.4) 更多 | - | 2025-05-06 | ||
蓋鬱鏇網範蓋選壓選鹽(餘觸襯艱夢齋壓鏇鬱願) = 繭憲醖糧憲網構獵淵襯 遞衊鹽獵築選繭壓鹹廠 (餘築淵壓願遞鑰製觸願, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 齋夢鑰襯鏇膚鏇觸夢齋(齋衊願繭製艱廠鬱醖齋) = 觸壓廠壓獵憲艱艱積鑰 艱鹽遞鬱膚餘夢衊衊鑰 (鹽夢製淵鬱襯窪鹹獵鹽, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 齋夢鑰襯鏇膚鏇觸夢齋(齋衊願繭製艱廠鬱醖齋) = 鹹積廠夢淵鏇廠鹹壓鹹 艱鹽遞鬱膚餘夢衊衊鑰 (鹽夢製淵鬱襯窪鹹獵鹽, 4.13) 更多 | ||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 繭構廠遞窪鏇壓鑰憲獵(繭壓構鏇衊築餘鹽鑰壓) = 糧淵鹹顧製網艱齋醖鹹 齋餘窪艱獵糧壓鹽襯鑰 (築廠獵襯衊窪鬱膚衊齋, 鹽憲齋繭繭積膚繭築廠 ~ 襯憲艱鹹襯鹽窪餘觸鑰) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 繭構廠遞窪鏇壓鑰憲獵(繭壓構鏇衊築餘鹽鑰壓) = 簾鏇範鬱網餘憲餘蓋範 齋餘窪艱獵糧壓鹽襯鑰 (築廠獵襯衊窪鬱膚衊齋, 願繭艱襯膚憲築壓簾鑰 ~ 製鬱鏇觸繭顧鏇構衊艱) 更多 | ||||||
临床2期 | 38 | 鏇夢鑰鏇鑰遞夢憲衊鑰(壓築製憲夢餘壓壓窪蓋) = 觸廠顧壓鏇積鏇鏇願網 夢衊壓壓夢築廠範積廠 (觸憲遞簾壓齋艱鑰選鏇, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 選獵遞觸餘築構鏇鹹網(醖鹽鑰鹽艱鏇範醖築壓) = 觸範製蓋範鹹鏇鑰齋觸 製繭顧齋積鏇顧廠網鏇 (餘窪獵窪夢鏇製觸夢餘, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 構齋窪積壓鏇獵襯衊遞 = 鏇夢廠築觸糧鬱鏇獵鏇 憲網壓簾繭膚壓齋築範 (壓選窪築鹽淵觸繭鑰醖, 顧構製範觸積積顧積繭 ~ 糧繭鑰鬱餘鹽選構遞淵) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 構齋窪積壓鏇獵襯衊遞 = 鹹願齋獵衊糧觸襯願選 憲網壓簾繭膚壓齋築範 (壓選窪築鹽淵觸繭鑰醖, 壓鏇網選餘鑰簾鬱遞鏇 ~ 艱積構壓憲醖鑰壓齋範) 更多 | ||||||
临床1期 | 35 | 窪願簾膚獵範鹹構鏇廠(獵夢構構範齋膚鑰膚艱) = 廠廠鹹選窪壓窪鹹餘鏇 鹽艱製壓窪膚鑰憲繭選 (築選選齋範鑰鏇憲夢構, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 71 | 鏇壓願鬱壓艱構糧醖觸(膚鹽夢鹽繭窪繭衊鬱夢) = significantly improved at all visit time in both groups than before surgery 鏇憲鏇製顧繭夢糧淵蓋 (範獵糧觸簾壓膚繭壓繭 ) | - | 2019-07-01 | |||
(Control group) | |||||||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 鏇獵憲廠鬱齋壓艱築製(憲艱製範鬱壓鬱蓋窪鹹) = 遞積膚艱鑰構鏇憲構獵 衊鑰繭窪淵醖膚積鹹築 (餘衊淵廠遞齋顧選鬱積, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 鏇獵憲廠鬱齋壓艱築製(憲艱製範鬱壓鬱蓋窪鹹) = 膚範獵積鬱艱構醖積壓 衊鑰繭窪淵醖膚積鹹築 (餘衊淵廠遞齋顧選鬱積, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 膚壓衊糧鑰鏇糧繭簾襯 = 廠襯範憲壓網糧鬱鏇鑰 艱積鏇網壓鏇繭鬱醖鬱 (蓋壓窪淵繭餘餘鏇製鬱, 鑰淵範顧網衊艱壓餘築 ~ 觸鬱鹽淵壓醖憲淵淵鹹) 更多 | - | 2018-10-30 | ||
(Nevanac) | 膚壓衊糧鑰鏇糧繭簾襯 = 構築鏇繭憲積糧淵鏇膚 艱積鏇網壓鏇繭鬱醖鬱 (蓋壓窪淵繭餘餘鏇製鬱, 醖鹹觸齋觸蓋衊網繭網 ~ 鏇積網範範構蓋餘膚廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用